N-acetyl lysyltyrosylcysteine amide

N-acetyl lysyltyrosylcysteine amide (KYC) is a tripeptide-based myeloperoxidase (MPO) inhibitor and redox-modulating agent under development for the treatment of inflammatory and oxidative stress-driven conditions, including diabetic cardiomyopathy and cardiovascular diseases. KYC works by inhibiting the enzymatic activity of MPO, thereby reducing the production of hypochlorous acid and other reactive oxygen species that contribute to tissue damage and fibrosis. In preclinical models of type 2 diabetes, KYC has been shown to improve cardiac function, reduce myocardial fibrosis, and modulate the immune system by expanding CD4+CD25+Foxp3+ regulatory T cells (Tregs) while dampening systemic inflammation. Additionally, KYC treatment has been associated with the activation of regulatory and antioxidative defense pathways, including the Nrf2 pathway. The drug is being developed by ReNeuroGen in collaboration with academic institutions such as the Medical College of Wisconsin.

Other names

N-acetyl-L-lysyl-L-tyrosyl-L-cysteine amideN-acetyl-Lys-Tyr-Cys-NH2N-acetyl-Lys-Tyr-Cys-NH-2N-acetyl-Lys-Tyr-Cys-NH 2